Papers/PMID:42101650
Placebo-controlled three-armed pilot trial of Escitalopram or Nortriptyline for depressive symptoms in Parkinson's disease (ADepT-PD).
Journal of neural transmission (Vienna, Austria : 1996)2026The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
escitalopram — no detected effect on beck Depression Inventory (BDI) total score
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“There were no statistically significant differences between the groups: the mean difference for change in BDI-II severity was − 3.1 (95% confidence interval (CI) -8.66 to 2.53, p = 0.28) for nortriptyline vs. placebo and − 0.7 (95% CI -6.11 to 4.70, p = 0.80) for escitalopram vs. placebo (Supplementary Table 3).”
Quoted verbatim from Placebo-controlled three-armed pilot trial of Escitalopram or Nortriptyline for depressive symptoms in Parkinson's disease (ADepT-PD).. - Study
- RCT
- Duration
- 8 weeks
- Dose
- target 20 mg/day in patients aged 65 or under, 10 mg/day in patients over 65 or with hepatic impairment, titrated from 5 mg in two-weekly steps
- Population
- People with Parkinson's disease and depressive symptoms (BDI-II 14 or above) in a three-arm pilot trial of escitalopram, nortriptyline or placebo; change from baseline to 8 weeks, escitalopram versus placebo
Effect -0.7 mean difference, 95% CI -6.11 to 4.7
Placebo-controlled three-armed pilot trial of Escitalopram or Nortriptyline for depressive symptoms in Parkinson's disease (ADepT-PD).2026PMID:42101650Permalink